APOBEC mutagenesis in EGFR mutant TKI resistance NSCLCs
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://www.omicsdi.org/dataset/ega/EGAS00001005526
下载链接
链接失效反馈官方服务：
资源简介：
Receptor tyrosine kinase (RTK)-activated lung cancers are characterized by alterations in oncogenic drivers that induce kinase activation with resultant tyrosine kinase inhibitor (TKI) resistance through both on-target and off-target mechanisms.
Focusing on a subgroup of 93 EGFR-mutant lung cancers with paired osimertinib-naïve and osimertinib-resistant tumor samples, we find a significant enrichment of kataegis, chromothripsis and APOBEC mutagenesis among the cancers treated with targeted therapy.
APOBEC mutagenesis and structural rearrangements are pervasive mechanisms by which RTK-driven lung cancers may evolve and develop drug resistance.EGA study EGAS00001005526
创建时间：
2024-10-07
